New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
07:05 EDTISISIsis Pharmaceuticals initiates Phase 1 study of ISIS-ANGPTL3 Rx
Isis Pharmaceuticals nannounced that it has initiated a Phase 1 clinical study for ISIS-ANGPTL3 Rx, an antisense drug targeting angiopoietin-like 3 protein, an independent risk factor for cardiovascular disease. ISIS-ANGPTL3 Rx is designed to act as a broad dyslipidemia agent. By reducing ANGPTL3, ISIS-ANGPTL3 Rx has the potential to reduce LDL-cholesterol and triglycerides, and to increase insulin sensitivity. Isis plans to evaluate ISIS-ANGPTL3 Rx in patients who have severe metabolic or cardiovascular disease and who would benefit from a drug that simultaneously addresses a variety of adverse lipid and metabolic parameters contributing to their disease.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
09:57 EDTISISLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 13, 2014
07:12 EDTISISOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use